UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)

Annals of oncology, 2018-10, Vol.29, p.viii102-viii102

2018

Volltextzugriff (PDF)

Prevention of Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation with Valganciclovir: Single Center Experience

Journal of chemotherapy (Florence), 2008-02, Vol.20 (1), p.140-142, Article 140

2008

Volltextzugriff (PDF)

3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting

Breast (Edinburgh), 2019-03, Vol.44, p.S68

2019

Volltextzugriff (PDF)

P156 - 3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting

Breast (Edinburgh), 2019-03, Vol.44, p.S68-S68

2019

Volltextzugriff (PDF)

319PA randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

O-027 A pivotal phase 3 trial of MABp1 in advanced colorectal cancer

Annals of oncology, 2016-06, Vol.27, p.ii128

2016

Volltextzugriff (PDF)

O-027A pivotal phase 3 trial of MABp1 in advanced colorectal cancer

Annals of oncology, 2016-06, Vol.27 (suppl_2), p.ii128-ii128

2016

Volltextzugriff (PDF)

One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment

Annals of oncology, 2017-09, Vol.28, p.v45-v45

2017

Volltextzugriff (PDF)

A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB

Annals of oncology, 2017-09, Vol.28, p.v238-v238

2017

Volltextzugriff (PDF)

Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Annals of oncology, 2017-09, Vol.28, p.v408-v409

2017

Volltextzugriff (PDF)

Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P5-P5-18-21

2012

Volltextzugriff (PDF)

Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC)

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.614-614

2011

Volltextzugriff (PDF)

A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): Safety results

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.e11097-e11097

2011

Volltextzugriff (PDF)

OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer

Cancer research (Chicago, Ill.), 2011-12, Vol.71 (24_Supplement), p.OT1-02-09-OT1-02-09

2011

Volltextzugriff (PDF)

Isolation and preliminary characteristics of '-N-acetylglucosaminidase in the sperm of Siberian sturgeon (Acipenser baerii) and rainbow trout (Oncorhynchus mykiss)

Journal of applied ichthyology, 2008-01, Vol.24 (4), p.492-496

2008

Volltextzugriff (PDF)

Characteristics of acid phosphatase from Russian sturgeon (Acipenser gueldenstaedtii) spermatozoa

Journal of applied ichthyology, 2006-01, Vol.22 (Suppl.), p.375-379

2006

Volltextzugriff (PDF)

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Annals of oncology, 2014-07, Vol.25 (7), p.1328

2014

Volltextzugriff (PDF)

Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P3-P3-09-01

2013

Volltextzugriff (PDF)

CVD BIO biochemotherapy of metastatic melanoma - one center clinical experience

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7563-7563

2004

Volltextzugriff (PDF)

CVD BIO biochemotherapy of metastatic melanoma - one center clinical experience

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.7563-7563

2004

Volltextzugriff (PDF)

Implementing a Thoracic Enhanced Recovery Program: Lessons Learned in the First Year

The Annals of thoracic surgery, 2018-06, Vol.105 (6), p.1597-1604

2018

Volltextzugriff (PDF)

MICRO-URZĄDZENIA, BEZPRZEWODOWE KAPSUŁKI, MAPY, STYMULATORY I ROZRUSZNIKI STOSOWANE DO DIAGNOSTYKI I LECZENIA ZABURZEŃ MOTORYKI PRZEWODU POKARMOWEGO

Wiadomości lekarskie (1960), 2024, Vol.77 (8)

Sarosiek, Irene

2024

Volltextzugriff (PDF)

p53: Jack of all (cell death) trades, master of all

Science translational medicine, 2018-01, Vol.10 (426)

Sarosiek, Kristopher

2018

Volltextzugriff (PDF)

Myc heals all (tumor) wounds

Science translational medicine, 2017-12, Vol.9 (420)

Sarosiek, Kristopher

2017

Volltextzugriff (PDF)

Searching for the ovarian cancer cell of origin

Science translational medicine, 2017-11, Vol.9 (414)

Sarosiek, Kristopher

2017

Volltextzugriff (PDF)

1 – 25 von 798

Suche als RSS-Feed

Aktive Filter

KollektionMEDLINE

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(749)
Mit Volltextzugriff
(603)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(5)
... seit 90 Tagen
(14)

Menü

Weitere Dienste

Einstellungen

A randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)

Prevention of Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation with Valganciclovir: Single Center Experience

3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting

P156 - 3-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2 positive early or locally advanced breast cancer in neoadjuvant setting

319PA randomized, open label, phase II study of prophylactic octreotide (OCT) to prevent/reduce the frequency and severity of diarrhea in patients (pts) receiving lapatinib (LAP) with capecitabine (CAP) for the treatment of metastatic breast cancer (mBC)

O-027 A pivotal phase 3 trial of MABp1 in advanced colorectal cancer

O-027A pivotal phase 3 trial of MABp1 in advanced colorectal cancer

One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment

A dose-response study of ramucirumab treatment in patients with gastric cancer/gastroesophageal junction adenocarcinoma: Primary results of 4 dosing regimens in the phase 2 trial I4T-MC-JVDB

Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Abstract P5-18-21: A Phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC)

Bosutinib (BOS) and letrozole (LET) versus LET alone as first-line treatment in postmenopausal women with advanced breast cancer (ABC)

A phase II randomized trial of lapatinib with either vinorelbine or capecitabine as first- and second-line therapy for ErbB2-overexpressing metastatic breast cancer (MBC): Safety results

OT1-02-09: A Phase II Randomized Trial of Lapatinib with Either Vinorelbine or Capecitabine as First- and Second-Line Therapy for HER2−Overexpressing Metastatic Breast Cancer

Isolation and preliminary characteristics of '-N-acetylglucosaminidase in the sperm of Siberian sturgeon (Acipenser baerii) and rainbow trout (Oncorhynchus mykiss)

Characteristics of acid phosphatase from Russian sturgeon (Acipenser gueldenstaedtii) spermatozoa

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy

Abstract P3-09-01: NEPA, a fixed-dose combination of netupitant and palonosetron, prevents chemotherapy-induced nausea and vomiting (CINV) more effectively and reduces the impact on daily living for breast cancer patients compared with palonosetron

CVD BIO biochemotherapy of metastatic melanoma - one center clinical experience

CVD BIO biochemotherapy of metastatic melanoma - one center clinical experience

Implementing a Thoracic Enhanced Recovery Program: Lessons Learned in the First Year

MICRO-URZĄDZENIA, BEZPRZEWODOWE KAPSUŁKI, MAPY, STYMULATORY I ROZRUSZNIKI STOSOWANE DO DIAGNOSTYKI I LECZENIA ZABURZEŃ MOTORYKI PRZEWODU POKARMOWEGO

p53: Jack of all (cell death) trades, master of all

Myc heals all (tumor) wounds

Searching for the ovarian cancer cell of origin

Aktive Filter

Suchergebnisse filtern